<DOC>
	<DOCNO>NCT00277355</DOCNO>
	<brief_summary>This study conduct assess impact minocycline progression symptom HD . The study also assess whether reasonable continue study minocycline HD . We measure effect minocycline HD measure change Huntington 's disease symptom .</brief_summary>
	<brief_title>Pilot Study Minocycline Huntington 's Disease</brief_title>
	<detailed_description>The DOMINO study randomize , double-blind , multi-center , futility study minocycline patient HD . Subjects randomize ( 3:1 ) one two study arm : ( 1 ) group receive active minocycline ( 100 mg po b.i.d . ) , ( 2 ) group receive placebo . Subjects enrol approximate six-month period remain blind study drug 18 month . The primary analysis involve comparison change time TFC minocycline group fix value determine historical control data . A placebo group also include facilitate blinding permit descriptive assessment validity assume change time historical control .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Age 18 year old Clinical feature HD confirmatory family history HD ; and/or genetically confirm HD Independently walk fully selfsufficient activity daily live ( eat , dress , bath ) Able take medication ( capsule ) mouth History know hypersensitivity intolerability minocycline know allergy tetracycline History vestibular disease Subjects underlie hematologic , hepatic renal disease History systemic lupus erythematosus ( SLE )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Study Minocycline Huntington 's Disease</keyword>
</DOC>